PACAP receptor PAC1 monoclonal antibody (mAb), AMG 301, showed no migraine prevention benefit, while the PACAP ligand mAb, Lu AG09222, notably reduced monthly migraine days in a phase 2 trial. Here, ADCYAP1 is linked to migraine disorder.